Completed
Phase 2
Age: 12Years +
All Genders
ID00001068
Influence of Risk Status for Disease Progression on the Response to Antiretroviral Interventions A Follow-up Study to ACTG 175
Led by National Institute of Allergy and Infectious Diseases (NIAID) · Updated on 2021-11-04
210
Participants Needed
41
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
To determine the influence of virus load, CD4 count, biologic phenotype, and presence of symptomatic disease on the response of HIV-infected patients to a new therapeutic regimen. PER AMENDMENT 8/27/96: To extend the availability of currently assigned ACTG 303 treatment for 6 months.
CONDITIONS
Brief Title
A Study of Disease Progression and Anti-HIV Treatments
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here